XML 90 R41.htm IDEA: XBRL DOCUMENT v3.19.3

Segments (Tables)

9 Months Ended

Sep. 30, 2019

Summary of Segment Profit

a. Segment information:

		Three months ended September 30, 2019
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	2,051			$	1,163			$	736
Gross profit			1,048				662				295
R&D expenses			156				63				21
S&M expenses			219				206				114
G&A expenses			112				56				32
Other income			(5	)			(4	)			(1	)
Segment profit		$	565			$	341			$	130

		Three months ended September 30, 2018
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	2,265			$	1,212			$	726
Gross profit			1,196				676				301
R&D expenses			158				62				21
S&M expenses			265				242				120
G&A expenses			128				74				37
Other (income) expense			(4	)			1				—
Segment profit		$	649			$	297			$	123

		Nine months ended September 30, 2019
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	6,169			$	3,611			$	2,145
Gross profit			3,155				2,066				877
R&D expenses			497				199				66
S&M expenses			756				637				348
G&A expenses			342				175				102
Other income			(6	)			(5	)			(2	)
Segment profit		$	1,566			$	1,060			$	363
		Nine months ended September 30, 2018
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	7,059			$	3,982			$	2,265
Gross profit			3,778				2,195				942
R&D expenses			528				208				70
S&M expenses			813				725				384
G&A expenses			357				243				115
Other income			(206	)			(1	)			(11	)
Segment profit		$	2,286			$	1,020			$	384

Schedule Of Consolidated Income Before Income Tax

		Three months ended								Nine months ended
		September 30,								September 30,
		2019				2018				2019				2018
		(U.S. $ in millions)								(U.S. $ in millions)
North America profit		$	565			$	649			$	1,566			$	2,286
Europe profit			341				297				1,060				1,020
International Markets profit			130				123				363				384
Total segments profit			1,036				1,069				2,989				3,690
Profit of other activities			16				35				92				87
			1,051				1,104				3,081				3,777
Amounts not allocated to segments:
Amortization			255				297				823				909
Other assets impairments, restructuring and other items			160				139				263				834
Goodwill impairment			—				—				—				300
Intangible asset impairments			177				519				1,206				1,246
Gain on divestitures, net of divestitures related costs			(3	)			(31	)			(12	)			(114	)
Other R&D expenses (income)			(7	)			60				(7	)			82
Costs related to regulatory actions taken in facilities			11				1				28				6
Legal settlements and loss contingencies			468				19				1,171				(1,239	)
Other unallocated amounts			72				84				201				226
Consolidated operating income (loss)			(81	)			16				(591	)			1,527
Financial expenses, net			211				229				635				736
Consolidated income (loss) before income taxes		$	(292	)		$	(213	)		$	(1,226	)		$	791

Schedule of Net Sales by Product Line

b. Segment revenues by major products and activities:

The following tables present revenues by major products and activities for the three months and the nine months ended September 30, 2019 and 2018:

		Three months ended September 30,
		2019				2018
		(U.S. $ in millions)
North America
Generic products		$	914			$	922
COPAXONE			271				463
BENDEKA/TREANDA			124				161
ProAir*			71				107
QVAR			60				36
AJOVY			25				—
AUSTEDO			105				62
Anda			351				333
Other			131				182
Total		$	2,051			$	2,265

* Does not include sales of ProAir authorized generic, which are included under generics products.

		Nine months ended September 30,
		2019				2018
		(U.S. $ in millions)
North America
Generic products		$	2,826			$	2,957
COPAXONE			753				1,403
BENDEKA/TREANDA			353				502
ProAir*			194				352
QVAR			183				173
AJOVY			68				—
AUSTEDO			276				136
Anda			1,080				984
Other			436				554
Total		$	6,169			$	7,059

* Does not include sales of ProAir authorized generic, which are included under generics products.

		Three months ended September 30,
		2019				2018
		(U.S. $ in millions)
Europe
Generic products		$	836			$	845
COPAXONE			106				124
Respiratory products			87				93
Other			134				150
Total		$	1,163			$	1,212

		Nine months ended September 30,
		2019				2018
		(U.S. $ in millions)
Europe
Generic products		$	2,599			$	2,749
COPAXONE			327				417
Respiratory products			267				312
Other			417				504
Total		$	3,611			$	3,982

		Three months ended September 30,
		2019				2018
		(U.S. $ in millions)
International markets
Generic products		$	474			$	498
COPAXONE			20				14
Distribution			176				149
Other			66				65
Total		$	736			$	726

		Nine months ended September 30,
		2019				2018
		(U.S. $ in millions)
International markets
Generic products		$	1,404			$	1,523
COPAXONE			46				52
Distribution			491				456
Other			204				233
Total		$	2,145			$	2,265

X

- Definition

Schedule of consolidated income before income tax.

+ References

No definition available.

+ Details

Name:	teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix:	teva_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration